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Background: Signiﬁcance of an ST-T abnormality in subjects with no apparent heart
diseases is to be determined.
Subjects and methods: The study involved 44,990 adults (16,368 males and 28,622
females) aged 40–85 years who underwent an annual health examination. Cardiovascular
risks (CVRs) were considered positive if 1) body mass index was 25Kg/m2, 2) systolic
blood pressure (BP)  130mmHg and/or diastolic BP  85mmHg, 3) triglyceride 150mg/
dl, 4) HDL-C level 40mg/dl for men and 50mg/dl for women, or 5) fasting blood glucose
110mg/dl. The relation between CVRs and ST-T abnormalities were evaluated.
Results: ST-T abnormalities were found in 6.49% in males, and more frequently in females:
8.45%. Each CVR and the number of combined CVRs were risk factors for ST-T
abnormalities on ECG (P < 0:0001 for a trend). On the other hand, ECG-based LVH was
found in 5.7% but showed no relation with CVRs or their combinations. ST-T abnormalities
may represent preclinical cardiac involvement of CVRs more sensitively than LVH on ECG
and ECG ﬁndings may be used in mass examinations.
Conclusions: ST-T abnormalities without apparent heart diseas may be considered to be
nonspeciﬁc but this cross-sectional study showed that they are related to CVRs and may be
used as an early marker of preclinical cardiac damage by CVRs.
(J Arrhythmia 2011; 27: 202–207)
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Introduction
Cardiovascular risks (CVRs) tend to cluster1)
much like metabolic syndrome (MS) which is
diagnosed when 3 or more of the ﬁve individual
components of CVRs are found together in the same
individual.2,3) Obesity was found to play a major role
in newly developed MS or clustering of CVRs.4–6)
MS has been shown to be associated with an
increased risk in developing type 2 diabetes mellitus
and cardiovascular events.7,8)
In our previous study,9) MS was found to be a risk
for new onset of atrial ﬁbrillation (AF). Furthermore,
the presence of premature beats and ST-T abnor-
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malities which are unrelated to left ventricular
hypertrophy (LVH) were additional risk factor for
new onset of AF.10) Though ST-T abnormalities on
the electrocardiogram (ECG) may indicate myocar-
dial ischemia, hypertrophy or inﬂammation of the
heart, they may be observed in subjects without
evidence of heart disease and regarded as a non-
speciﬁc ECG ﬁnding, but the clinical signiﬁcance of
ST-T abnormalities needs to be elucidated.
In the present study, we investigated the relation
between CVRs and their clustering and ST-T
abnormalities which could be seen in the subjects
without apparent heart diseases. We analyzed the
data of the annual health examination performed in
the general population.
Subjects and methods
We included 44,990 Japanese adults (16,368
males and 28,622 females) who underwent an annual
health examination in Niigata, Japan in 2003. The
mean age was 61:4 12:3 years. The examination
was primarily recommended for those who were
healthy and not under current medication.
After a comprehensive health questionnaire, an-
thropometric data (body weight and height) was
collected. Blood pressure measurements as well as
standard 12-lead electrocardiographic examinations
were undertaken for each individual. Basic labora-
tory tests were performed for all subjects which
included serum total cholesterol, high-density lip-
oprotein cholesterol (HDL-C), complete blood cell
count, fasting blood glucose [FBG], hemoglobin A1c
(HbA1c), serum creatinine (serum Cr), ALT and
AST.
CVRs were diagnosed by the following criteria:
1) body mass index (BMI)  25Kg/m2, 2) high
blood pressure (BP) systolic BP  130mmHg
and/or diastolic BP  85mmHg), 3) fasting hyper-
triglyceridaemia (TG)  150mg/dl), 4) low HDL-C
level  40mg/dl for men and  50mg/dl for
women, and 5) high fasting blood glucose (FBG)
 110mg/dl.
BMI was calculated by dividing the body weight
in kilograms by the square of the height in meters
and this was used instead of waist circumference
which was not available in our database at that time.
Because of the diﬀerences in obesity between
Japanese and Western populations, BMI of  25
kg/m2 was considered elevated in contrast to
 30 kg/m2 as in Western populations according
to criteria of the Japan Society for the Study of
Obesity.11–13)
Cardiac abnormalities
As with our previous study,10) the Minnesota Code
was used based on computer-based electrocardio-
gram (ECG) diagnosis.14,15) A ST-T abnormality was
diagnosed if the subject had any of the following
criteria: (1) a mild ST-segment abnormality exhibit-
ing a ﬂat T wave (code 5-3 or 5-4), or a negative
or biphasic T wave (negative-positive type) with a
negative phase < 1:0mm (code 5-3); and (2) a
severe ST-segment abnormality exhibiting a nega-
tive or biphasic T wave (negative-positive type)
with a negative phase  1:0mm (code 5-1 or 5-2),
horizontal or downward sloping ST-segment depres-
sion  0:5mm (code 4-1or 4-2), or upward sloping
ST depression  1:0mm (code 4-4). Typical ST-T
abnormalities are shown in Figure 1.
ST-T abnormalities in the presence of left ven-
tricular hypertrophy (LVH) were excluded from the
ST-T abnormality category and were classiﬁed as
LVH which were diagnosed according to the high
amplitude R-wave criteria (code 3-1 or 3-3).
Flat T-wave Negative T-wave ST-segment depression
Figure 1 ST-segment abnormalities.
Left: Flat T wave. The T-wave amplitude was
positive and the T/R ratio was less than 1/20th
(Code 5-3 or 5-4). Center: T waves with
negative phase 1:0mm and ST segment de-
pression (Code 5-1). Right: ST-segment depres-
sion 0:5mm (Code 4-2).
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Data analysis
The prevalence of each CVR and clustering was
determined and the relation between CVR or their
combinations and the ECG abnormalities; ST-T
abnormality and LVH, were determined. Continuous
variables were expressed as mean  SD. The Stu-
dent’s t-test was used to compare means across
each nominal factor with 2 levels, while one-way
ANOVA was used to compare several means across
a categorical factor with many levels. The Welch’s
test or chi-square test was used to compare propor-
tions and for trend analysis. The odds ratio (OR)
and 95% conﬁdence interval were calculated to
ascertain the contribution of clustering of CVRs on
ECG abnormalities.
All statistical analyses were performed with SPSS,
version 12.0 (SPSS Inc, Chicago, IL). A two-sided P
value < 0:05 was considered statistically signiﬁcant.
Results
Clustering of risk factors
The prevalence of each CVR in the 44,990
subjects is shown in Table 1. Except in subjects with
BMI  25Kg/m2, CVRs were more prevalent in
males than females (P < 0:0001).
As the number of CVR combinations rose, the
number of subjects declined rapidly: 16,590, 15,795,
8,342, 3,222, 916, and 125 for 0 to 5 CVRs,
respectively. Clustering with 3 or more CVRs was
observed in 13.8%, more often in males than
females: 17.9% vs. 13.4% (P < 0:0001). Blood
pressure rose as the number of CVRs increased
from 0 to 5 in both genders (Table 2).
ST-T abnormality
An abnormal ST-T was found in 7.7%: 6.49% for
males and 8.45% for females. In most cases, they
Table 1 Prevalence of each cardiovascular risk (CVR)




(n ¼ 77;593) p value
BMI  25Kg/m2 25.4% 22.8% 26.8% <0:0001
Abnormal BP 51.6% 58.2% 48.1% <0:0001
Hypertriglyceridaemia 25.8% 28.1% 24.6% <0:0001
Low HDL-C 6.1% 10.0% 4.0% <0:0001
Abnormal FBG 23.9% 30.1% 20.6% <0:0001
BMI: body mass index, BP: arterial blood pressure, HDL-C: high-density lipoprotein cholesterol, FBG: fasting blood glucose


















systolic BP 114:8 9:6 131:4 17:0 138:2 16:5 141:5 15:7 144:9 15:2 146:6 13:6 <0:0001
diastolic BP 69:0 8:0 76:1 10:5 78:8 10:4 80:3 10:4 81:5 10:3 81:4 10:2 <0:0001
Male
systolic BP 116:9 9:1 133:2 17:4 139:4 16:7 142:2 16:2 145:2 15:7 146:3 13:1 <0:0001
diastolic BP 70:5 7:9 77:5 10:8 80:1 10:6 81:5 10:4 82:8 10:5 82:7 9:6 <0:0001
Female
systolic BP 114:3 9:8 130:4 16:7 137:4 16:2 140:1 15:4 141:7 14:0 140:1 14:0 <0:0001
diastolic BP 68:5 7:9 75:3 10:3 78:0 10:2 79:4 10:2 80:5 10:0 79:7 10:7 <0:0001
CVR: cardiovascular risk, BP: blood pressure in mmHg

















ST-T abn. 4.9% 8.4% 10.5% 10.6% 12.4% 14.4% <0:0001
LVH 4.0% 7.1% 6.5% 5.4% 4.4% 6.0% NS
LVH: left ventricular hypertrophy, ST-T abn.: ST-T abnormality
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were mild ST-T abnormalities (>90%). As the
number of CVRs increased, the prevalence of ST-T
abnormalities also increased (Table 3). Gender (fe-
male) and age were risk factors for ST-T abnormal-
ities: OR ¼ 1:33 for an increment of 1 year (1.23–
1.43 of 95% conﬁdence) and OR ¼ 1:04 (1.04–1.05
of 95% conﬁdence), respectively (P < 0:0001 for
both). After adjustment for age and gender, the
number of CVRs were still a risk for ST-T
abnormalities as shown in Figure 2.
Left ventricular hypertrophy
LVH was found in 5.7%, more often in males
compared to females: 7.9% vs. 3.2% (P < 0:0001).
In the subjects with clustering of CVRs 3, LVH
was associated with higher blood pressure: 148:3
16:6=82:2 11:6mmHg vs. 142:1 1:5=80:6
10:3mmHg (systolic/diastolic) (P < 0:001). Simi-
larly, in the subjects with 0-2 CVRs, BP was higher
in those with LVH compared to those without LVH:
137:5 18:4=78:3 11:1mmHg vs. 127:9 17:4
mmHg/74:6 10:4mmHg (P < 0:001). Totally,
blood pressure rose as the number of CVRs increas-
ed (Table 2) but, the prevalence of LVH remained
unchanged (Table 3).
Discussion
In the present study, each CVR was found to be a
risk for ST-T abnormalities and as the number of
CVRs increased from 0 to 5, the prevalence increas-
ed steadily (Table 3). However, LVH was found less
often than an ST-T abnormality and was associated
with higher blood pressure but was unrelated to CVR
or the clustering of CVRs (Table 3). A close relation
of ST-T abnormalities and CVR or the clustering of
CVRs suggested that ST-T abnormalities could be
the result of preclinical cardiac involvement of CVRs
and they may be more useful markers than LVH in
assessing cardiac status in mass examinations.
Clustering of CVRs, like MS, has been shown to
accelerate cardiovascular16,17) and renal disease18)
and increase morbidity and mortality as well as all-
cause mortality.16,17,19) In the Strong Heart Study,16)
participants with MS had greater LV chamber
diameter, relative wall thickness, and left ventricular
(LV) mass compared to the non-MS group. Among
components of MS, the presence of high BP was
associated with greater LV diameter (5:02 0:46 vs.
4:90 0:46, p ¼ 0:001), LV mass (42:0 9:4 vs.
37:5 9:0 g/m, p < 0:001) and the prevalence of
LVH (25.0% vs. 11.4%, p < 0:001). In the sub-
sequent echocardiographic examination, of 612 non-
diabetic participants with ATP III-deﬁned MS,
43.2% of subjects with MS had LVH, but LVH
was seen only in 11.7% of those without MS
(p < 0:001).17) This ﬁnding means that MS is
associated with a 2.6-fold likelihood of LVH and
2.3-fold higher likelihood of LA dilatation.17)
Furthermore, the subjects with high to normal
blood pressure in MS subjects were shown to have
similar LV geometry and function as untreated
hypertensive non-MS patients16) and in MS subjects,
hyperinsulinism, hyperleptinemia, renin-angioten-
sin-system or catecholamine were suggested to be
involved in the development of LVH.20,22)
However, the ECG based diagnosis of LVH was
associated with higher blood pressure but showed
no relation with clustering of CVRs in the present
study (Table 3). This lack of a relation between
CVRs and LVH might be due to either ﬁnding that
LVH was uncommon because of relatively lower
blood pressure or because ECG was less sensitive to
assess LVH. Actually, ECG is known to be less
sensitive in detecting LVH than echocardiography:
the sensitivity of diagnosis of LVH is reported to
be 1–44% by ECG vs. 16–74% by echocardiogra-
phy.23,24)
On the other hand, ST-T abnormalities may be




Figure 2 The number of cardiovascular
risks (CVR)s and odds ratio for ST-T abnor-
malities.
As the number of CVRs increased, the preva-
lence of odds ratio increased (p < 0:0001 for a
trend). However, this was not the case for LVH
based on ECG. ST-T abnormalities can be more
sensitive in representing subclinical cardiac
involvements by multiple CVRs.
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whom heart disease or hypertension is denied.14)
Such ECG changes are considered to be non-speciﬁc
without clinical signiﬁcance. In the present study,
ST-T abnormalities were found to be closely
associated with clustering of CVRs (Figure 2).
Previously, we demonstrated that ST-T abnormal-
ities were risks for new onset of atrial ﬁbrillation.10)
In the Strong Heart Study,16) MS was found to be
associated with greater LA diameter and a reduced E/
A ratio as shown by echocardiography, suggesting that
the left atrium was under overload. If ST-T abnor-
malities represent preclinical damage of LV caused by
latent cardiac ﬁbrosis with latent LVH, LV may
become less compliant leading to pressure overload of
the left atrium and then to new onset atrial ﬁbrilla-
tion.10) The close association of ST-T abnormalities
with clustering of CVRs suggests that ST-T abnor-
malities on ECG can be amarker of preclinical cardiac
involvement of CVRs, and so-called nonspeciﬁc ST-T
abnormalities in subjects with no apparent heart
diseases may have clinical signiﬁcance.
There are some limitations. We used BMI instead
of waist circumference for the diagnosis of obesity
because waist circumference was not measured at
that time, but waist circumference is now essential
for the diagnosis of MS in many criteria. However,
BMI is a marker of obesity closely associated with
waist circumference17,18) and MS deﬁned with use of
BMI has been shown to have clinical signiﬁcance as
reported earlier.5,6,9,10) We excluded ST-T abnormal-
ities which were associated with LVH. This is
because we attempted to elucidate factors which may
result in so-called non-speciﬁc ST-T abnormalities
on ECG. As to the risk for development of
cardiovascular events, ST-T abnormalities associat-
ed with LVH might play more important roles.
Whether the subjects with ST-T abnormalities have
abnormal cardiac function or pathology or not is to
be determined. Since the study was cross-sectional,
the outcomes of the subjects with ST-T abnormal-
ities were not elucidated.
In conclusion, CVRs and their clustering showed a
relationship with the prevalence of ST-T abnormal-
ities, but not with LVH. An ST-T abnormality can be
an early marker of cardiac involvement by CVRs.
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